<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04814732</url>
  </required_header>
  <id_info>
    <org_study_id>2020-012-GLOB3</org_study_id>
    <nct_id>NCT04814732</nct_id>
  </id_info>
  <brief_title>Expanded Access Program of Surufatinib</brief_title>
  <official_title>An Expanded Access Program of Surufatinib for Patients With Advanced or Metastatic Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <brief_summary>
    <textblock>
      This treatment protocol is intended to provide early access of surufatinib to patients with&#xD;
      locally advanced or metastatic NETs for whom, in the opinion of their treating physician,&#xD;
      other treatment options or surufatinib clinical trials in this indication are unsuitable.&#xD;
      This EAP is currently available in the US only.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior to any assessments, all subjects must provide a signed ICF. Prior to inclusion in the&#xD;
      program, the patients must undergo all appropriate screening procedures to check for&#xD;
      eligibility.&#xD;
&#xD;
      Once eligibility is confirmed, patients will receive treatment with surufatinib 300mg, orally&#xD;
      (PO), daily (QD). All patients will undergo continuous monitoring for safety until the end of&#xD;
      treatment.&#xD;
&#xD;
      There is no pre-defined duration of treatment for each patient. Patients will be treated&#xD;
      until progressive disease (as defined by treating physician), unacceptable toxicity, death,&#xD;
      withdrawal from program, the treatment becomes commercially available, or halting of product&#xD;
      development.&#xD;
&#xD;
      A follow-up clinic visit is recommended for all patients approximately 30 days after last&#xD;
      dose of treatment to complete the final safety assessments, as applicable.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Neuroendocrine Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib</intervention_name>
    <description>HMP-012</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically documented, well differentiated, locally advanced or&#xD;
             metastatic NETs&#xD;
&#xD;
          2. The patient or parent/legal guardian (as appropriate) is willing and able to provide&#xD;
             informed consent, and where required, the patient is willing to provide assent&#xD;
&#xD;
          3. ≥12 years of age&#xD;
&#xD;
          4. In the opinion of the patient's treating physician, other treatment options or&#xD;
             clinical trials in this indication are unsuitable&#xD;
&#xD;
          5. Patient has adequate bone marrow and organ function&#xD;
&#xD;
          6. Urine dipstick ≤1+ for proteinuria or ≤30 mg/dL in urinalysis,&#xD;
&#xD;
          7. ECOG ≤2 for adult patients (≥18 years of age), Karnofsky ≥60 for patients &gt;16 and &lt;18&#xD;
             years of age, and Lansky ≥60 for pediatric patients ≤16 years of age&#xD;
&#xD;
          8. For female patients of childbearing potential and male patients with partners of&#xD;
             childbearing potential, agreement (by patient and partner) to use a highly effective&#xD;
             form(s) of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrollable hypertension, as defined by local institution&#xD;
&#xD;
          2. Gastrointestinal disease or condition that the physician suspects may affect drug&#xD;
             absorption&#xD;
&#xD;
          3. History or presence of a serious hemorrhage&#xD;
&#xD;
          4. Clinically significant cardiovascular disease&#xD;
&#xD;
          5. Brain metastases and/or spinal cord compression untreated with surgery and/or&#xD;
             radiotherapy&#xD;
&#xD;
          6. High risk of bleeding at screening due to tumor invasion&#xD;
&#xD;
          7. Arterial thrombosis or deep venous thrombosis within 6 months prior to first dosing or&#xD;
             thromboembolic events (including stroke and/or transient ischemic attack) within 6&#xD;
             months prior to first dosing&#xD;
&#xD;
          8. Received treatment with anticancer therapy, including investigational therapy, within&#xD;
             7 days or 5 half-lives (whichever is longer)&#xD;
&#xD;
          9. Received prior treatment with surufatinib&#xD;
&#xD;
         10. Inability to take medication orally&#xD;
&#xD;
         11. Any other clinically significant comorbidities that, in the judgment of the treating&#xD;
             physician, could predispose the patient to safety risks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>John Kauh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hutchison Medipharma Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leslie Callahan, BSN,MS</last_name>
    <phone>+1 973-826-5578</phone>
    <email>lesliec@hutch-med.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shujie Han</last_name>
    <email>ExpandedAccess@hmplglobal.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jennifer Hege</last_name>
      <phone>303-385-2067</phone>
      <email>jennifer.hege@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Allen L Cohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center, Medical Oncology &amp; Hematology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Alexandra Cline</last_name>
      <phone>410-951-7956</phone>
      <email>acline@mdmercy.com</email>
    </contact>
    <investigator>
      <last_name>Sandy D Kotiah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MidAmerica Cancer Care</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jennifer Ross</last_name>
      <phone>660-383-3197</phone>
      <email>jross@maccsp.com</email>
    </contact>
    <investigator>
      <last_name>Jaswinder Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Michelle MacKenzie</last_name>
      <phone>973-538-5210</phone>
      <email>mmackenzie@summithealth.com</email>
    </contact>
    <investigator>
      <last_name>David Gallison, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Jonathan Huntzinger</last_name>
      <phone>214-370-1942</phone>
      <email>Jonathan.huntzinger@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Andrew S Paulson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Tracy Taylor</last_name>
      <phone>801-507-3953</phone>
      <email>tracy.taylor@imail.org</email>
    </contact>
    <investigator>
      <last_name>Mark A Lewis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Cancer Center</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Emily Lowe</last_name>
      <phone>435-251-4746</phone>
      <email>Emily.lowe@imail.org</email>
    </contact>
    <investigator>
      <last_name>Ryan Wilcox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

